Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine
12:11pm, Friday, 05'th Mar 2021
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
Novartis Lends Support To Manufacture CureVac's COVID-19 Shots
08:37am, Thursday, 04'th Mar 2021
Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molecu
COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine
11:27am, Friday, 12'th Feb 2021
Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session. US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE)
CureVac's stock is up 6% as it begins regulatory process for its COVID-19 vaccine in the E.U.
08:02am, Friday, 12'th Feb 2021
Shares of CureVac gained 6.0% in premarket trading on Friday after the company said it started a rolling submission for its experimental mRNA-based COVID-19 vaccine in the European Union. The vaccine
CureVac working on a second generation vaccine to combat Covid variants, CEO says
05:58am, Friday, 12'th Feb 2021
CureVac CEO Franz-Werner Haas discusses the firm's plans to tackle new Covid-19 variants.
UK Government teams up with CureVac to find mutant COVID-19 vaccine
02:54pm, Sunday, 07'th Feb 2021
The UK government has said it is to join forces with German group CureVac BV (NASDAQ:CVAC) to develop vaccines capable of dealing with mutations in the coronavirus (COVID-19) virus. Britain has initia
U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week
10:04am, Saturday, 06'th Feb 2021
U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week
CureVac Shares Gain After UK Backs Company's Vaccine Development Efforts For COVID-19 Variants
11:02am, Friday, 05'th Feb 2021
The U.K. has entered into a collaboration accord with CureVac NV (NASDAQ: CVAC) to develop messenger ribonucleic acid (mRNA)-based vaccine candidates against COVID-19 variants. CureVac will del
CureVac to develop new variant vaccines for the U.K.
10:42am, Friday, 05'th Feb 2021
Shares of CureVac gained 7.7% in trading on Friday after the company said it plans to develop COVID-19 vaccine candidates that can prevent infection with new variants as part of an agreement with the
CureVac Joins GlaxoSmithKline to Make Next-Gen Covid Shot
04:32pm, Wednesday, 03'rd Feb 2021
Feb.03 -- CureVac has joined forces with GlaxoSmithKline Plc to create a next-generation Covid mRNA shot that could help protect against multiple variants of the pathogen, and it's extended a partne
GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at once
06:55am, Wednesday, 03'rd Feb 2021
UK pharma giant GlaxoSmithKline (GSK) and German biotech CureVac plan to co-develop "next generation" vaccines that could work against multiple coronavirus variants at once, the companies announced We
GSK and CureVac join forces to develop vaccines targeting new COVID-19 variants
04:45am, Wednesday, 03'rd Feb 2021
GSK and CureVac said their approach could potentially tackle multiple coronavirus strains in one vaccine shot
CureVac aims to raise $450 million through public offering
08:13am, Thursday, 28'th Jan 2021
Shares of CureVac were down 3.1% in premarket trading on Thursday after the German company said it aims to raise $450 million through a follow-up public offering. CureVac, which went public in August,
CureVac: Smart Money Is On COVID-19 Vaccine Approval
11:30am, Friday, 15'th Jan 2021
CureVac shares currently trade at $100.6 - down from nearly $150 in early December. The mRNA specialist IPO'd at a price of just $16 in August last year, but shares have spiked in anticipation of an a
CureVac partners with Bayer to accelerate vaccine production
04:44pm, Tuesday, 12'th Jan 2021
Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.
